Filing Overview
ORIC Pharmaceuticals, Inc. filed a Form 8-K dated October 21, 2023, with the report signed on October 23, 2023. The company is a Delaware corporation headquartered in South San Francisco, California, and its common stock trades on Nasdaq under the symbol ORIC.
Business Context and Event
Under Item 8.01, ORIC announced initial data from the ongoing Phase 1 dose-escalation trial of ORIC-114 in patients with EGFR- or HER2-exon 20-mutated non-small cell lung cancer. The data were presented at the European Society for Medical Oncology Congress 2023.
The filing incorporates by reference a press release dated October 21, 2023, filed as Exhibit 99.1. The press release text and underlying clinical data are not included in the provided filing content.
Financial and Operating Metrics
- The filing does not provide revenue, net income or loss, cash flow, margins, cash balances, debt, liquidity, or other financial metrics.
- The filing does not provide a clear value for enrollment, response rates, duration of response, safety findings, dosing, or other trial results.
Changes, Outlook, and Risks
- The material event disclosed is the presentation of initial ORIC-114 Phase 1 dose-escalation data.
- No financial guidance, development timeline, regulatory outlook, or management forecast is provided in the filing text.
- No specific risks, contingencies, unusual accounting items, or financing actions are disclosed in the provided content.
Investor Verification Items
- Review Exhibit 99.1 for the complete ORIC-114 clinical results, including efficacy, safety, dose levels, and patient population.
- Verify whether the initial data support continued dose escalation or expansion of the trial.
- Assess subsequent filings for updated clinical results, regulatory developments, cash runway, financing needs, and pipeline prioritization.
- Confirm the filing’s reported date and the October 23, 2023 signature date.